Vicore Pharma Holding (NASDAQ:VCRE) Sees Significant Growth in Short Interest

Vicore Pharma Holding (NASDAQ:VCRE) was the target of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 10,709 shares, an increase of 941.7% from the October 15th total of 1,028 shares. Based on an average trading volume of 22,655 shares, the short-interest ratio is presently 0.5 days.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Chardan Capital initiated coverage on shares of Vicore Pharma in a report on Wednesday, November 4th. They set a “buy” rating and a $15.00 target price for the company. Jefferies Financial Group began coverage on shares of Vicore Pharma in a report on Friday, October 9th. They issued a “buy” rating and a $25.00 price target for the company. Weiss Ratings initiated coverage on shares of Vicore Pharma in a research report on Thursday, October 8th. They issued a “sell (e-)” rating for the company. Finally, Wall Street Zen raised Vicore Pharma to a “hold” rating in a research note on Saturday, October 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Vicore Pharma currently has a consensus rating of “Hold” and an average price target of $20.00.

Vicore Pharma Trading Up 0.7%

Shares of NASDAQ:VCRE traded up $0.08 during trading on Tuesday, hitting $11.35. 24,639 shares of the company’s stock traded hands, compared to its average volume of 26,533. Vicore Pharma has a 52 week low of $7.88 and a 52 week high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last posted its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million during the quarter.

About Vicore Pharma

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs. Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.